Table 1. Spearman’s rank correlation between microRNA-22 and microRNA-26 and the clinical variables.

<table>
<thead>
<tr>
<th>miR</th>
<th>clinical variable</th>
<th>Age</th>
<th>Disease duration</th>
<th>ESR</th>
<th>CRP</th>
<th>SJC</th>
<th>TJC</th>
<th>DAS-28</th>
<th>ACPA</th>
<th>RF</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-22</td>
<td></td>
<td>0.09</td>
<td>0.27</td>
<td>0.41</td>
<td>0.49</td>
<td>0.26</td>
<td>0.21</td>
<td>0.33</td>
<td>0.24</td>
<td>0.16</td>
</tr>
<tr>
<td>miR-26a</td>
<td></td>
<td>0.2</td>
<td>0.14</td>
<td>0.49</td>
<td>0.41</td>
<td>0.43</td>
<td>0.74</td>
<td>0.63</td>
<td>0.26</td>
<td>0.16</td>
</tr>
</tbody>
</table>

The significant correlations were bolded and indicated by red. Abbreviations: ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; SJC, swollen joint count; TJC, tender joint count; DAS-28, disease activity score 28; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.443

PsA treatment: what is new?

**POS0192**

PROGNOSTIC FACTORS ASSOCIATED WITH ACHIEVING MINIMAL DISEASE ACTIVITY IN EARLY PSORIATIC ARTHRITIS PATIENTS

E. Loginova1, T. Korotaeva1, E. Gubarev1, S. Glukhovska1, V. A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow, Russian Federation; V. A. Nasonova Research Institute of Rheumatology, Medical and Social Problems in Rheumatology, Moscow, Russian Federation

Background: The goal of treat to target strategy (T2T) in psoriatic arthritis (PsA) is attaining remission or minimal disease activity (MDA). The benefits of T2T have been seen recently [1]. But prognostic factors for MDA achievement within 12 months (mos) of treatment according to T2T strategy in PsA patients (pts) at an early stage hasn’t been studied yet.

Objectives: To determine the prognostic factors associated with MDA achievement within 12 months (mos) of treatment according to T2T strategy in PsA pts.

Methods: 77 pts (M/F=36/41) with early active PsA fulfilling the CASPAR criteria were included. Mean age 36.9±10.45 yrs., PsA duration 11.1±10.0 mos., Psoriasis (PsO) duration 82.8±92.1 mos. At baseline (BL) and at 12 mos. of therapy PsA activity by tender joint count (TJC)/swelling joint count (SJC)/66, Pain (VAS), Patient global assessment disease activity (PGA), VAS, CRP mg/l, dactylitis, enthesitis by LEI and plantar fascia, BSA (%), HAQ and fatigue by FACIT (Functional Assessment of Chronic Illness Therapy) Fatigue Scale (Version 4) were evaluated. A score FACIT <30 indicates severe fatigue and > 30 – less fatigue. All pts were given therapy with Methotrexate (MTX) s/c. After 3-9 mos. of ineffectiveness of MTX treatment 29 pts were given biologic DMARDs.

Results: By 12 mos. of therapy, the proportion of pts who had reached MDA (5/7) were calculated. Pts were split into 2 groups: MDA+ (n=45) and MDA− (n=32). The results of one-factor model of logistic regression showed the following features at BL were associated with MDA by 12 mos: age, gender, disease duration, age of PsA, PsO duration, PGA, TJC+SJC<3, CRP≤5 mg/l, Pain≤0.5 mg/l, FACIT<30 points, absence of enthesitis, dactylitis and PsO - that constitutes a clinical prognostic factors for MDA achievement within 12 mos of T2T strategy in early PsA pts.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1704

**POS0193**

DAS28-CRP GUIDED TREAT-TO-TARGET TAPERING OF TUMOR NECROSIS FACTOR INHIBITORS IN PSORIATIC ARTHRITIS: A RETROSPECTIVE COHORT STUDY.

C. Michielsens1,2, N. Den Broeder1,2, M. Mulder1,2, M. Wenink1, F. Van den Hoogen1,2, L. M. Verhoeven1, A. Den Broeder1,2, S. Sant Maartenskliniek, Rheumatology, Nijmegen, Netherlands; 1Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, Netherlands

Background: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of psoriatic arthritis (PsA) [1]. However, they carry disadvantages, such as adverse effects, patient burden, and costs, which could be reduced by treat-to-target (T2T) tapering. Although there is lack of high level evidence, guidelines suggest that T2T tapering and discontinuation might be considered, but no studies comparing this strategy to continuation in PsA were published [2].

Objectives: To assess the effect of T2T TNFi tapering on disease activity and TNFi dosage in PsA patients with low disease activity (LDA).

Methods: PsA patients using TNFi who visited the clinic between April 2012 and October 2018 were included if eligible for tapering, according to local protocol: ≥ 6 months of TNFi treatment and ≥ 6 months of at least LDA (DAS28-CRP < 2.4 or ≥ 2.9 in patients with disease duration > 3 years) or by judgement of physician and patient). Patients with concomitant inflammatory disease preventing tapering were excluded. Three different time periods were defined: i) full-dose TNFi continuation; ii) TNFi tapering; iii) stable TNFi dosage after tapering. A mixed-model analysis was used to estimate mean DAS28-CRP during these three time periods. This model included: age, gender, disease duration, the following time-varying components: current dose reduction status (three time periods mentioned above), time since eligibility for tapering and use of concomitant conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs), and a random intercept to account for inter-patient variability. Furthermore, a mean percentage of the Daily Defined Dose (%DDD) was calculated as secondary outcome.

Results: 152 patients were included, with a mean of 6.5 DAS28-CRP measurements, of whom 125 attempted dose reduction during follow-up. Median follow-up duration was 41 months (Inter Quartile Range (IQR) 24-59) for patients who never attempted dose reduction and 43 months (IQR 28-58) for those who did (table 1). The mixed model showed no significant difference in DAS28-CRP between the three time periods. Adjusted for gender, age, disease duration at baseline, time since follow-up and csDMARD use, the mean DAS28-CRP was 1.91 in the continuation period (95% Confidence Interval (CI) [1.76-2.03]) and 2.0 in both the TNFi tapering (95%CI [1.90-2.12], difference with continuation: 0.11, p=0.19) and stable TNFi dosage after tapering (95%CI 1.88-2.11), difference with continuation: 0.09, p=0.31) period. The mean percentage of the DDD for the three time periods was 107% for the continuation period; 62% in the TNFi tapering period and 79% in the stable TNFi dosage period.

Conclusion: T2T tapering of TNFi appears to have no negative effects on disease activity in PsA patients compared with full dose continuation, and reduces